Genmab (GMAB)
(Delayed Data from NSDQ)
$28.24 USD
-0.11 (-0.39%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $28.24 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value A Growth D Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GMAB 28.24 -0.11(-0.39%)
Will GMAB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GMAB
Wall Street Analysts Think Genmab (GMAB) Could Surge 45.08%: Read This Before Placing a Bet
Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat
GMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
All You Need to Know About Genmab (GMAB) Rating Upgrade to Strong Buy
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
Other News for GMAB
What 8 Analyst Ratings Have To Say About Genmab
J&J wins another FDA label expansion for multiple myeloma therapy
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Genmab (GMAB) and Penumbra (PEN)
Strong Buy Rating for Genmab’s Stock Backed by FDA Approval and Positive Clinical Data
Baird Q2 2024 International And Global Growth Fund Commentary